Merck advances phase 3 trial for islatravir as once-monthly oral PrEP for women at high risk for acquiring HIV-1

Merck advances phase 3 trial for islatravir as once-monthly oral PrEP for women at high risk for acquiring HIV-1. (Credit: PublicDomainPictures from Pixabay)